NCT03320941 is a Phase 2 clinical trial of LIK066 in Obesity, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT03320941?

NCT03320941 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT03320941?

Interventions in NCT03320941: LIK066, Placebo.

Is NCT03320941 still recruiting?

NCT03320941 is currently completed. Last updated 26 June 2024.

Are results published for NCT03320941?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-06-26 · How we verify

NCT03320941

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

Completed Phase 2 Results posted Last updated 26 June 2024

What this trial tests

Phase 2 trial testing LIK066 in Obesity in 126 participants. Completed in 25 July 2018.

Timeline

7 December 2017

Primary endpoint
25 July 2018

25 July 2018

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	126
Start date	7 December 2017
Primary completion	25 July 2018
Estimated completion	25 July 2018
Sites	24 locations across Japan

Drugs / interventions tested

LIK066 — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 20 to 75, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage Change From Baseline in Body Weight at Week 12 Primary · Baseline, Week 12

The dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment.

Group	Value	95% CI
LIK066 2.5mg qd	-1.86	-2.59 – -0.67
LIK066 10mg qd	-2.84	-3.79 – -2.16
LIK066 25 mg qd	-3.41	-3.96 – -2.84
LIK066 50 mg qd	-3.80	-4.48 – -3.17
Placebo	0.11	-0.90 – 0.97

Responder Rates According to Percentage Decrease in Body Weight From Baseline to Week 12 Secondary · Baseline, Week 12

The responder rates according to percentage decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 No Statistical Analysis for \>=5% and \>=10% was not calculated due to division by zero

>= 3%

Group	Value	95% CI
LIK066 2.5mg qd	15.8
LIK066 10mg qd	55.6
LIK066 25 mg qd	50.0
LIK066 50 mg qd	56.7
Placebo	7.1

>= 5%

Group	Value	95% CI
LIK066 2.5mg qd	5.3
LIK066 10mg qd	27.8
LIK066 25 mg qd	17.9
LIK066 50 mg qd	26.7
Placebo	0.0

>= 10%

Group	Value	95% CI
LIK066 2.5mg qd	0.0
LIK066 10mg qd	0.0
LIK066 25 mg qd	0.0
LIK066 50 mg qd	3.3
Placebo	0.0

>= 3% (Dysglycemic)

Group	Value	95% CI
LIK066 2.5mg qd	12.5
LIK066 10mg qd	75.0
LIK066 25 mg qd	38.5
LIK066 50 mg qd	46.2
Placebo	7.7

>= 5% (Dysglycemic)

Group	Value	95% CI
LIK066 2.5mg qd	0.0
LIK066 10mg qd	62.5
LIK066 25 mg qd	23.1
LIK066 50 mg qd	23.1
Placebo	0.0

>= 10% (Dysglycemic)

Group	Value	95% CI
LIK066 2.5mg qd	0.0
LIK066 10mg qd	0.0
LIK066 25 mg qd	0.0
LIK066 50 mg qd	0.0
Placebo	0.0

>= 3% (T2DM)

Group	Value	95% CI
LIK066 2.5mg qd	18.2
LIK066 10mg qd	40.0
LIK066 25 mg qd	60.0
LIK066 50 mg qd	64.7
Placebo	6.7

>= 5% (T2DM)

Group	Value	95% CI
LIK066 2.5mg qd	9.1
LIK066 10mg qd	0.00
LIK066 25 mg qd	13.3
LIK066 50 mg qd	29.4
Placebo	0.00

Percentage Change From Baseline in Body Weight at Week 12 in Dysglycemic Participants and Participants With Type 2 Diabetes Mellitus (T2DM) Secondary · Baseline, Week 12

The dose-response relationship for weight loss in dysglycemic participants and participants with T2DM. Percentage change from baseline in body weight at Week 12.

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-1.90	-3.17 – -0.37
LIK066 10mg qd	-2.95	-3.95 – -2.15
LIK066 25 mg qd	-3.29	-4.19 – -2.57
LIK066 50 mg qd	-3.47	-4.31 – -2.54
Placebo	0.00	-1.25 – 1.19

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	-1.64	-2.54 – -0.26
LIK066 10mg qd	-2.66	-3.49 – -1.16
LIK066 25 mg qd	-3.42	-4.30 – -2.42
LIK066 50 mg qd	-4.23	-5.63 – -3.27
Placebo	0.10	-1.40 – 1.48

Change From Baseline at Week 12 on Waist Circumference at Umbilical Level Secondary · Baseline, Week 12

Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	-2.47	-4.003 – -0.937
LIK066 10mg qd	-2.63	-4.172 – -1.082
LIK066 25 mg qd	-2.65	-3.907 – -1.393
LIK066 50 mg qd	-3.11	-4.320 – -1.895
Placebo	-1.37	-2.636 – -0.100

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-2.78	-5.187 – -0.368
LIK066 10mg qd	-4.49	-6.856 – -2.123
LIK066 25 mg qd	-2.08	-3.977 – -0.177
LIK066 50 mg qd	-2.23	-4.123 – -0.333
Placebo	-0.41	-2.312 – 1.483

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	-2.22	-4.156 – -0.283
LIK066 10mg qd	-1.39	-3.418 – 0.631
LIK066 25 mg qd	-2.90	-4.557 – -1.244
LIK066 50 mg qd	-3.88	-5.416 – -2.340
Placebo	-2.19	-3.859 – -0.520

Percentage Change From Baseline at Week 12 on Hemoglobin A1c (HbA1c) Secondary · Baseline, Week 12

HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	-0.285	-0.415 – -0.155
LIK066 10mg qd	-0.355	-0.488 – -0.223
LIK066 25 mg qd	-0.366	-0.473 – -0.259
LIK066 50 mg qd	-0.418	-0.521 – -0.314
Placebo	-0.079	-0.187 – 0.028

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-0.139	-0.261 – -0.016
LIK066 10mg qd	-0.184	-0.306 – -0.062
LIK066 25 mg qd	-0.196	-0.292 – -0.101
LIK066 50 mg qd	-0.163	-0.259 – -0.067
Placebo	-0.050	-0.146 – 0.046

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	-0.405	-0.616 – -0.195
LIK066 10mg qd	-0.491	-0.708 – -0.275
LIK066 25 mg qd	-0.502	-0.679 – -0.325
LIK066 50 mg qd	-0.618	-0.784 – -0.452
Placebo	-0.093	-0.271 – 0.086

Change From Baseline at Week 12 on Fasting Plasma Glucose (FPG) Secondary · Baseline, Week 12

FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	-0.334	-0.652 – -0.016
LIK066 10mg qd	-0.665	-0.990 – -0.340
LIK066 25 mg qd	-0.747	-1.007 – -0.486
LIK066 50 mg qd	-0.986	-1.238 – -0.733
Placebo	-0.160	-0.423 – 0.103

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	0.002	-0.322 – 0.326
LIK066 10mg qd	-0.126	-0.453 – 0.200
LIK066 25 mg qd	-0.262	-0.515 – -0.008
LIK066 50 mg qd	-0.472	-0.728 – -0.217
Placebo	-0.217	-0.471 – 0.038

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	-0.606	-1.095 – -0.118
LIK066 10mg qd	-1.111	-1.619 – -0.604
LIK066 25 mg qd	-1.145	-1.559 – -0.730
LIK066 50 mg qd	-1.377	-1.766 – -0.988
Placebo	-0.079	-0.497 – 0.339

Change From Baseline at Week 12 on Systolic Blood Pressure (SBP) Secondary · Baseline, Week 12

After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	-4.90	-9.049 – -0.746
LIK066 10mg qd	-5.12	-9.403 – -0.834
LIK066 25 mg qd	-6.36	-9.781 – -2.935
LIK066 50 mg qd	-6.94	-10.233 – -3.655
Placebo	-5.36	-8.758 – -1.961

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-5.79	-12.457 – 0.883
LIK066 10mg qd	-7.10	-13.825 – -0.369
LIK066 25 mg qd	-3.58	-8.811 – 1.657
LIK066 50 mg qd	-4.17	-9.399 – 1.051
Placebo	-7.09	-12.294 – -1.891

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	-4.16	-9.414 – 1.091
LIK066 10mg qd	-2.96	-8.500 – 2.588
LIK066 25 mg qd	-8.63	-13.143 – -4.120
LIK066 50 mg qd	-9.00	-13.182 – -4.810
Placebo	-3.77	-8.255 – 0.724

Change From Baseline at Week 12 on Diastolic Blood Pressure (DBP) Secondary · Baseline, Week 12

After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	-3.72	-6.803 – -0.627
LIK066 10mg qd	-3.54	-6.700 – -0.377
LIK066 25 mg qd	-4.36	-6.892 – -1.818
LIK066 50 mg qd	-5.23	-7.677 – -2.788
Placebo	-3.12	-5.647 – -0.597

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-3.32	-8.404 – 1.769
LIK066 10mg qd	-4.40	-9.490 – 0.699
LIK066 25 mg qd	-2.46	-6.441 – 1.513
LIK066 50 mg qd	-4.25	-8.230 – -0.279
Placebo	-4.31	-8.257 – -0.357

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	-4.00	-7.943 – -0.059
LIK066 10mg qd	-2.45	-6.584 – 1.687
LIK066 25 mg qd	-5.98	-9.352 – -2.607
LIK066 50 mg qd	-5.92	-9.066 – -2.776
Placebo	-1.93	-5.303 – 1.448

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Triglycerides (TG) Secondary · Baseline, Week 12

Fasting lipid profile (Triglycerides (TG)), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	1.840	-30.956 – 34.636
LIK066 10mg qd	11.057	-22.372 – 44.487
LIK066 25 mg qd	43.928	17.118 – 70.737
LIK066 50 mg qd	5.307	-20.648 – 31.261
Placebo	17.401	-9.474 – 44.275

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-1.153	-62.637 – 60.331
LIK066 10mg qd	-1.986	-64.104 – 60.132
LIK066 25 mg qd	52.284	3.839 – 100.729
LIK066 50 mg qd	14.061	-34.625 – 62.746
Placebo	20.962	-27.416 – 69.340

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	1.016	-36.069 – 38.100
LIK066 10mg qd	23.108	-14.937 – 61.153
LIK066 25 mg qd	34.747	3.600 – 65.893
LIK066 50 mg qd	-0.057	-29.478 – 29.363
Placebo	13.806	-17.085 – 44.697

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Total Cholesterol Secondary · Baseline, Week 12

Fasting lipid profile (total cholesterol), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	-1.290	-6.809 – 4.229
LIK066 10mg qd	-2.983	-8.711 – 2.745
LIK066 25 mg qd	0.884	-3.663 – 5.430
LIK066 50 mg qd	0.302	-4.096 – 4.700
Placebo	-2.244	-6.800 – 2.312

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-3.055	-12.284 – 6.173
LIK066 10mg qd	-6.017	-15.916 – 3.882
LIK066 25 mg qd	4.273	-3.085 – 11.630
LIK066 50 mg qd	-1.734	-9.000 – 5.532
Placebo	-3.559	-10.940 – 3.822

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	0.158	-6.814 – 7.129
LIK066 10mg qd	-1.367	-8.670 – 5.937
LIK066 25 mg qd	-1.646	-7.772 – 4.481
LIK066 50 mg qd	1.817	-3.857 – 7.491
Placebo	-0.671	-6.635 – 5.294

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - High Density Lipoprotein (HDL) Secondary · Baseline, Week 12

Fasting lipid profile (HDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	1.499	-3.683 – 6.682
LIK066 10mg qd	-2.461	-7.790 – 2.868
LIK066 25 mg qd	-5.253	-9.514 – -0.993
LIK066 50 mg qd	0.112	-4.014 – 4.237
Placebo	-3.454	-7.739 – 0.830

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-0.519	-9.144 – 8.107
LIK066 10mg qd	0.329	-8.368 – 9.027
LIK066 25 mg qd	-3.279	-10.056 – 3.498
LIK066 50 mg qd	-0.147	-6.917 – 6.622
Placebo	-4.329	-11.096 – 2.437

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	2.886	-3.774 – 9.545
LIK066 10mg qd	-4.696	-11.654 – 2.261
LIK066 25 mg qd	-6.993	-12.672 – -1.315
LIK066 50 mg qd	0.235	-5.133 – 5.604
Placebo	-2.677	-8.484 – 3.130

Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Low Density Lipoprotein (LDL) Secondary · Baseline, Week 12

Fasting lipid profile (LDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12

Overall Study

Group	Value	95% CI
LIK066 2.5mg qd	0.757	-7.220 – 8.734
LIK066 10mg qd	-2.363	-10.702 – 5.975
LIK066 25 mg qd	0.037	-6.524 – 6.598
LIK066 50 mg qd	4.726	-1.616 – 11.068
Placebo	-0.552	-7.154 – 6.051

Dysglycemic

Group	Value	95% CI
LIK066 2.5mg qd	-3.065	-16.507 – 10.376
LIK066 10mg qd	-4.473	-18.904 – 9.958
LIK066 25 mg qd	2.579	-8.102 – 13.259
LIK066 50 mg qd	2.128	-8.426 – 12.681
Placebo	-3.994	-14.722 – 6.735

T2DM

Group	Value	95% CI
LIK066 2.5mg qd	3.727	-6.379 – 13.833
LIK066 10mg qd	-1.562	-12.127 – 9.004
LIK066 25 mg qd	-1.295	-10.099 – 7.510
LIK066 50 mg qd	6.803	-1.311 – 14.917
Placebo	2.942	-5.699 – 11.584

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events (AEs) were collected till the end of the study.(about 12 weeks) and serious adverse events (SAEs) were collected until 30 days after the last study visit (12 weeks + 30 days = about 114 days). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

LIK066 2.5mg qd

Serious: 0/19 (0%)

Deaths: 0/19

LIK066 10mg qd

Serious: 0/19 (0%)

Deaths: 0/19

LIK066 25mg qd

Serious: 0/28 (0%)

Deaths: 0/28

LIK066 50mg qd

Serious: 1/31 (3%)

Deaths: 0/31

Placebo

Serious: 0/29 (0%)

Deaths: 0/29

Serious adverse events (1 terms)

Reaction	System	LIK066 2.5mg qd	LIK066 10mg qd	LIK066 25mg qd	LIK066 50mg qd	Placebo
Cholecystitis acute	Hepatobiliary disorders	—	—	—	—	—

Other adverse events (32 terms — click to expand)

Reaction	System	LIK066 2.5mg qd	LIK066 10mg qd	LIK066 25mg qd	LIK066 50mg qd	Placebo
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—
Flatulence	Gastrointestinal disorders	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—
Protein urine present	Investigations	—	—	—	—	—
Urine albumin/creatinine ratio increased	Investigations	—	—	—	—	—
Hypoglycaemia	Metabolism and nutrition disorders	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—
Gastric polyps	Gastrointestinal disorders	—	—	—	—	—
Gastritis erosive	Gastrointestinal disorders	—	—	—	—	—
Large intestine polyp	Gastrointestinal disorders	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—
Malaise	General disorders	—	—	—	—	—
Hepatic steatosis	Hepatobiliary disorders	—	—	—	—	—
Asymptomatic bacteriuria	Infections and infestations	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—
Gingivitis	Infections and infestations	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—
Post-traumatic neck syndrome	Injury, poisoning and procedural complications	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—
White blood cells urine positive	Investigations	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Neck pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Periarthritis	Musculoskeletal and connective tissue disorders	—	—	—	—	—
Haematuria	Renal and urinary disorders	—	—	—	—	—
Pollakiuria	Renal and urinary disorders	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—
Eczema	Skin and subcutaneous tissue disorders	—	—	—	—	—
Urticaria	Skin and subcutaneous tissue disorders	—	—	—	—	—

Most-reported serious reactions: Cholecystitis acute.

Data from ClinicalTrials.gov NCT03320941 adverse events section.

Sponsor's own description

The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to support dose selection for Phase 3 development in Japanese adults with obesity disease.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Son JW, Kim S. · · 2020 · cited 92× · PMID 33389955 · DOI 10.4093/dmj.2020.0258
The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture.
Dong B, Lv R, Wang J, Che L, et al · · 2022 · cited 23× · PMID 35872985 · DOI 10.3389/fendo.2022.918350
Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Yokote K, Sano M, Tsumiyama I, Keefe D. · · 2020 · cited 15× · PMID 32072763 · DOI 10.1111/dom.14006
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity.
Zhang J, Wei J, Lai W, Sun J, et al · · 2025 · cited 2× · PMID 40004115 · DOI 10.3390/ijms26041651

Verify or expand the search:

Other trials of LIK066

Trials testing the same drug.

NCT03205150 — Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients · Phase 2 · completed
NCT03152552 — A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabete · Phase 2 · terminated
NCT03152591 — Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome · Phase 2 · completed
NCT03198767 — Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066 · Phase 2 · completed
NCT03100058 — A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults · Phase 2 · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03320941 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 26 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03320941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03320941

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (1 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of LIK066

Other recruiting trials for Obesity

Other Novartis Pharmaceuticals trials

Verify against primary sources